Incyte Corporation
INCY
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor tā¦ read more
Healthcare
Biotechnology
31 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$86.92
Price+0.88%
$0.76
1Y
Price
Market Cap
$16.973b
Large
Price/Earnings 3y Avg5y Avg
20.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+43.9%
EBITDA Margin+33.3%
Net Profit Margin+21.6%
Free Cash Flow MarginRevenue
$4.585b
+8.1%
1y CAGR+10.6%
3y CAGR+11.4%
5y CAGREarnings
$870.870m
+2570.2%
1y CAGR+850.3%
3y CAGR+621.7%
5y CAGREPS
$4.40
+2833.3%
1y CAGR+937.8%
3y CAGR+687.2%
5y CAGRBook Value
$0.00
$5.821b
Assets-
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
$288.810m
+16.0%
1y CAGR-26.1%
3y CAGR-5.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company